These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906 [TBL] [Abstract][Full Text] [Related]
29. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature]. Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442 [TBL] [Abstract][Full Text] [Related]
30. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Kröger N; Perez-Simon JA; Myint H; Klingemann H; Shimoni A; Nagler A; Martino R; Alegre A; Tomas JF; Schwerdtfeger R; Kiehl M; Fauser A; Sayer HG; Leon A; Beyer J; Zabelina T; Ayuk F; San Miguel JF; Brand R; Zander AR Biol Blood Marrow Transplant; 2004 Oct; 10(10):698-708. PubMed ID: 15389436 [TBL] [Abstract][Full Text] [Related]
31. [High-dose treatment of systemic AL-amyloidosis with autologous stem cell support]. Schjesvold FH; Sjo M; Tangen JM; Hammerstrøm J; Brinch L Tidsskr Nor Laegeforen; 2008 Jun; 128(12):1392-6. PubMed ID: 18552900 [TBL] [Abstract][Full Text] [Related]
32. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation. Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846 [TBL] [Abstract][Full Text] [Related]
33. [Comparison of autologous and allogeneic hematopoietic stem cell transplantation for 140 patients with de novo acute leukemia in first complete remission]. Wang HH; Feng SZ; Wang M; Wei JL; Jiang EL; Zhang L; Huang Y; Zhou SY; Liu QG; Qiu LG; Han MZ; Yan WW Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):389-92. PubMed ID: 15355688 [TBL] [Abstract][Full Text] [Related]
34. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251 [TBL] [Abstract][Full Text] [Related]
35. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. Porrata LF; Gertz MA; Litzow MR; Lacy MQ; Dispenzieri A; Inwards DJ; Ansell SM; Micallef IN; Gastineau DA; Elliott M; Hogan WJ; Hayman SR; Tefferi A; Markovic SN Clin Cancer Res; 2005 Feb; 11(3):1210-8. PubMed ID: 15709191 [TBL] [Abstract][Full Text] [Related]
36. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation. Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284 [TBL] [Abstract][Full Text] [Related]
37. High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors. Diaz MA; Vicent MG; Madero L Bone Marrow Transplant; 1999 Dec; 24(11):1157-9. PubMed ID: 10642802 [TBL] [Abstract][Full Text] [Related]